Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
    • Facilities
    • State Disclosures
  • Therapeutic Areas Overview
    • Central Nervous System
      • Fibromyalgia
      • Cocaine Intoxication
      • Migraine
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • COVID-19
      • Mpox (Monkey Pox)
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
      • TNX-1300
      • TNX-1900
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-801
      • TNX-1800
      • TNX-4200 CD45
    • Rare Disease
      • TNX-2900
    • Expanded Access Policy
  • Medicines
  • Clinical Trials
  • News & Events
    • Press Releases
    • Tonix in the News
    • Tonix Sponsored News
    • Investor Presentations
    • Scientific Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
      • Investor Presentations
      • Scientific Presentations
      • Program Specific Presentations
      • Fact Sheet
      • Conference Materials
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Multimedia

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Tonix in the News
    • Tonix Sponsored News
    • IR Events
    • Email Alerts
    • Op-Eds
  • Presentations
  • Multimedia
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • Form 8937
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
Tonix Pharmaceuticals Talks Focus on Filing New Drug Application of Tonmya for Fibromyalgia
Apr 30, 2024

Tonix Pharmaceuticals Talks Focus on Filing New Drug Application of Tonmya for Fibromyalgia

A Nasal Spray to Curb Excessive Eating in Prader-Willi
May 11, 2023

A Nasal Spray to Curb Excessive Eating in Prader-Willi

Seth Lederman, Co-Founder, CEO & Chairman of Tonix Pharmaceuticals discusses the state of Covid-19 in the U.S. and China
Jan 9, 2023

Seth Lederman, Co-Founder, CEO & Chairman of Tonix Pharmaceuticals discusses the state of Covid-19 in the U.S. and China

 Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King
Aug 31, 2022

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King
Aug 16, 2022

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by Bloomberg Radio
Aug 12, 2022

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by Bloomberg Radio

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King
Jun 9, 2022

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King
May 6, 2022

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King
Feb 11, 2022

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King
Dec 11, 2021

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King
Oct 5, 2021

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King

Tonix Pharmaceuticals CEO Seth Lederman returns to New to the Street
Aug 6, 2021

Tonix Pharmaceuticals CEO Seth Lederman returns to New to the Street

Bitterroot leaders welcome Tonix Pharmaceuticals, see bioscience potential
Jun 25, 2021

Bitterroot leaders welcome Tonix Pharmaceuticals, see bioscience potential

Tonix Pharmaceuticals CEO, Seth Lederman, talks about their Company’s pharmaceutical products
Jun 23, 2021

Tonix Pharmaceuticals CEO, Seth Lederman, talks about their Company’s pharmaceutical products

Dr. Seth Lederman joins the Becker’s Panel to discuss the future of value in biopharma - The Becker’s Panel - June 10, 2021
Jun 10, 2021

Dr. Seth Lederman joins the Becker’s Panel to discuss the future of value in biopharma - The Becker’s Panel - June 10, 2021

Dr. Seth Lederman discusses T Cell Immunity and COVID-19 on Technology Networks
Apr 28, 2021

Dr. Seth Lederman discusses T Cell Immunity and COVID-19 on Technology Networks

Dr. Seth Lederman interviewed on ABC FOX Montana to discuss highlights of Tonix’s planned vaccine manufacturing facility in Hamilton, MT
Jan 6, 2021

Dr. Seth Lederman interviewed on ABC FOX Montana to discuss highlights of Tonix’s planned vaccine manufacturing facility in Hamilton, MT

Covid-19 Is Not Going to Go Away: Tonix Pharmaceuticals CEO
Dec 7, 2020

Covid-19 Is Not Going to Go Away: Tonix Pharmaceuticals CEO

Dr. Seth Lederman interviewed on Contagion Live to discuss its COVID-19 vaccine in development.
Dec 4, 2020

Dr. Seth Lederman interviewed on Contagion Live to discuss its COVID-19 vaccine in development.

Developing a PTSD Therapeutic - Phase 3 Clinical Development
Nov 12, 2020

Developing a PTSD Therapeutic - Phase 3 Clinical Development

rss_feed RSS
  • Page 1
  • Page 2
  • Next Pagearrow_forward
email icon Sign up for Email Alerts
twitter icon linkedin icon facebook icon
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

© 2025 Tonix Pharmaceuticals Holding Corp.